PE20230735A1 - Metodos de tratamiento de trastornos del desarrollo con gaboxadol - Google Patents

Metodos de tratamiento de trastornos del desarrollo con gaboxadol

Info

Publication number
PE20230735A1
PE20230735A1 PE2022002752A PE2022002752A PE20230735A1 PE 20230735 A1 PE20230735 A1 PE 20230735A1 PE 2022002752 A PE2022002752 A PE 2022002752A PE 2022002752 A PE2022002752 A PE 2022002752A PE 20230735 A1 PE20230735 A1 PE 20230735A1
Authority
PE
Peru
Prior art keywords
gaboxadol
treatment
methods
developmental disorders
administrable
Prior art date
Application number
PE2022002752A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of PE20230735A1 publication Critical patent/PE20230735A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta referida a una composicion que comprende gaboxadol o una sal farmaceuticamente aceptable del mismo para su uso en el tratamiento del sindrome X fragil siendo una forma de dosificacion oral, administrable de tal manera que la dosis de gaboxadol dentro de un periodo de 24 horas es entre 5 mg y 30 mg. Asimismo, en donde la cantidad total de gaboxadol o sal farmaceuticamente aceptable del mismo administrable dentro de un periodo de 24 horas es entre 5 mg y 20 mg.
PE2022002752A 2015-07-17 2016-07-14 Metodos de tratamiento de trastornos del desarrollo con gaboxadol PE20230735A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
PCT/US2016/042238 WO2017015049A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (1)

Publication Number Publication Date
PE20230735A1 true PE20230735A1 (es) 2023-05-03

Family

ID=57774846

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2018000085A PE20190338A1 (es) 2015-07-17 2016-07-14 Metodos de tratamiento de trastornos del desarrollo con gaboxadol
PE2022002752A PE20230735A1 (es) 2015-07-17 2016-07-14 Metodos de tratamiento de trastornos del desarrollo con gaboxadol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2018000085A PE20190338A1 (es) 2015-07-17 2016-07-14 Metodos de tratamiento de trastornos del desarrollo con gaboxadol

Country Status (16)

Country Link
US (8) US20170014393A1 (es)
EP (1) EP3324961A4 (es)
JP (3) JP2018520189A (es)
KR (1) KR20180031721A (es)
CN (2) CN108024997A (es)
AU (2) AU2016295138B2 (es)
BR (1) BR112018000933A2 (es)
CA (1) CA2992734A1 (es)
CL (1) CL2018000142A1 (es)
CO (1) CO2018000375A2 (es)
HK (1) HK1250951A1 (es)
IL (2) IL256912B2 (es)
MX (2) MX2018000745A (es)
PE (2) PE20190338A1 (es)
TW (2) TW202325293A (es)
WO (1) WO2017015049A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
JP2018520189A (ja) 2015-07-17 2018-07-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ガボキサドールでの発達障害の処置方法
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
AU2018309049A1 (en) 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
JP2021527087A (ja) * 2018-06-14 2021-10-11 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． アンジェルマン症候群の処置におけるＭＩＲ−９２ａまたはＭＩＲ−１４５の使用
CA3110218A1 (en) * 2018-08-22 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
MX2021003302A (es) * 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
CN114072154B (zh) * 2018-11-21 2024-03-08 塞迪戈Abc有限责任公司 用于治疗精神障碍的加波沙朵和锂的组合物
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
KR20210105387A (ko) 2018-12-17 2021-08-26 오비드 테라퓨틱스 인크. 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용
AU2020288999A1 (en) * 2019-06-07 2022-02-03 Paxmedica, Inc. Compositions and methods for treating central nervous system disorders
KR20220035195A (ko) * 2019-07-15 2022-03-21 오비드 테라퓨틱스 인크. 치료적 치료를 위한 가복사돌을 포함하는 약학적 제제
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
EP4153549A2 (en) 2020-05-20 2023-03-29 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1345602B1 (en) * 2000-11-30 2010-07-21 Novodermix International Limited Wound healing
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
WO2005094820A1 (en) 2004-04-02 2005-10-13 H. Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
ZA200607427B (en) * 2004-04-02 2009-02-25 Lundbeck & Co As H Treatment of impaired respiratory function with gaboxadol
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
EP2578216A1 (en) * 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Methods of treating fragile x syndrome
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CA2732636A1 (en) * 2008-09-01 2009-05-07 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
CN103228142A (zh) 2010-09-28 2013-07-31 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
EP2765989B1 (en) 2011-10-13 2016-04-13 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents
EP4335505A3 (en) * 2012-11-30 2024-06-05 The Regents of The University of California Anticonvulsant activity of steroids
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
JP2018520189A (ja) 2015-07-17 2018-07-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ガボキサドールでの発達障害の処置方法
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
CA2994952A1 (en) 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Also Published As

Publication number Publication date
US20170014393A1 (en) 2017-01-19
US20180338960A1 (en) 2018-11-29
CO2018000375A2 (es) 2018-04-19
JP2023103375A (ja) 2023-07-26
US20180098974A1 (en) 2018-04-12
US20190117632A1 (en) 2019-04-25
KR20180031721A (ko) 2018-03-28
MX2022004734A (es) 2022-05-13
CA2992734A1 (en) 2017-01-26
US20230071127A1 (en) 2023-03-09
US20190321342A1 (en) 2019-10-24
EP3324961A4 (en) 2019-03-13
CN116531370A (zh) 2023-08-04
CL2018000142A1 (es) 2018-07-13
US20190255027A1 (en) 2019-08-22
IL305342A (en) 2023-10-01
TW201707700A (zh) 2017-03-01
AU2021250862A1 (en) 2021-11-04
TW202325293A (zh) 2023-07-01
MX2018000745A (es) 2018-08-15
CN108024997A (zh) 2018-05-11
TWI819995B (zh) 2023-11-01
JP2021130687A (ja) 2021-09-09
HK1250951A1 (zh) 2019-01-18
WO2017015049A1 (en) 2017-01-26
IL256912B2 (en) 2024-01-01
EP3324961A1 (en) 2018-05-30
PE20190338A1 (es) 2019-03-07
BR112018000933A2 (pt) 2018-09-04
AU2021250862B2 (en) 2023-11-09
AU2016295138B2 (en) 2021-11-04
JP2018520189A (ja) 2018-07-26
US11096929B2 (en) 2021-08-24
US20210030727A1 (en) 2021-02-04
IL256912A (en) 2018-03-29
IL256912B1 (en) 2023-09-01
AU2016295138A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
PE20230735A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
PH12016502556A1 (en) Intermittent dosing of mdm2 inhibitor
CL2019000485A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional.
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
AR097590A1 (es) Métodos para tratar el síndrome del x frágil y trastornos relacionados
IN2013MU03428A (es)
AR106477A1 (es) Combinación farmacéutica de antagonista del receptor nk3 y biguanidas
MX366118B (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.